ExpansionJul 21, 2026, 08:08 AM
VivoSim Labs Secures First Commercial Sales in China
AI Summary
VivoSim Labs, Inc. announced its first commercial sales in China, marking a significant expansion into the world's second-largest pharmaceutical market. The company secured two initial engagements with a leading Shanghai-based oncology biotech and a large Chengdu-based pharmaceutical company for its NAMkind™ toxicology and efficacy testing services. This move validates VivoSim's channel strategy and positions it to tap into an addressable China market estimated at approximately $2 billion, growing at a 10% CAGR, driven by increasing regulatory and scientific adoption of non-animal testing methods.
Key Highlights
- Secured first commercial sales in China for NAMkind™ testing services.
- Initial engagements with a Shanghai-based oncology biotech and a Chengdu-based pharmaceutical company.
- China is the world's second-largest pharmaceutical market.
- China's NMPA approved a record 76 innovative drugs in 2025, up from 48 in 2024.
- Addressable China market for liver and GI in vitro models estimated at ~$2 billion, growing at 10% CAGR.
- NAMkind™ Liver model achieved 91% predictive accuracy, 90% sensitivity, and 95% specificity.
- Late-stage clinical trial failure can cost $50 million to $200 million.
- FDA's April 2025 plan to phase out animal testing requirements for certain drugs.
Price Impact
More from VIVS